The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea

  • Kwon, Osung (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Jung-Min (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Do-Yoon (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Se Hun (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Pil Hyung (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Soo-Jin (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Seung-Whan (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Young-Hak (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Cheol Whan (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Seong-Wook (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Duk-Woo (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Seung-Jung (Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2016.11.14
  • Accepted : 2017.03.27
  • Published : 2018.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Compared with metallic drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS) may further improve long-term outcomes of percutaneous coronary intervention (PCI) in patients with coronary artery disease. We report our early experience with BVS in Korea. Methods: We evaluated 105 consecutive patients with BVS implanted at Asan Medical Center, Korea between October 21, 2015 and June 3, 2016. Angiographic results, and in-hospital and 6-month clinical outcomes were assessed. Results: A total of 134 BVS were implanted to treat 115 lesions. The mean age was $62{\pm}10.5years$; 85 patients (81%) were males, 26 patients (25%) were presented with acute coronary syndrome. Among 115 lesions treated with BVS, 76 (66.1%) were B2/C type, 27 (23.5%) were bifurcation lesions, and four (3.5%) were chronic total occlusion. Pre-dilation and post-dilation using high-pressure non-compliant balloon was performed in 104 lesions (90.4%) and 113 lesions (98.2%), respectively. During the procedure, intravascular imaging was used for all patients (100%; intravascular ultrasound 89 and optical coherence tomography 40 patients). Device success rate was 100%. In-segment and in-scaffold acute again were $1.1{\pm}0.6$ and $1.3{\pm}0.5mm$, respectively. Periprocedural myocardial infraction occurred in four patients (3.8%). No deaths, stent thrombosis, or urgent revascularizations occurred either during hospitalization or the follow-up period. Conclusions: In this single-center experience, implantation of BVS with intravascular imaging support was feasible and early clinical outcomes were excellent. Evaluation of long-term efficacy and safety of BVS and its feasibility in clinical use for a broader range of lesions is warranted.

Keywords

Acknowledgement

Supported by : Cardio Vascular Research Foundation

References

  1. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619. https://doi.org/10.1093/eurheartj/ehu278
  2. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008;358:342-352. https://doi.org/10.1056/NEJMoa0706258
  3. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011;123:779-797. https://doi.org/10.1161/CIRCULATIONAHA.110.971606
  4. Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 2014;129:211-223. https://doi.org/10.1161/CIRCULATIONAHA.113.001790
  5. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33:16-25. https://doi.org/10.1093/eurheartj/ehr384
  6. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomized controlled trial. Lancet 2015;385:43-54. https://doi.org/10.1016/S0140-6736(14)61455-0
  7. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015;373:1905-1915. https://doi.org/10.1056/NEJMoa1509038
  8. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015;36:3332-3342. https://doi.org/10.1093/eurheartj/ehv435
  9. Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol 2015;66:2298-2309. https://doi.org/10.1016/j.jacc.2015.09.054
  10. Stone GW, Gao R, Kimura T, et al. 1-Year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 2016;387:1277-1289. https://doi.org/10.1016/S0140-6736(15)01039-9
  11. Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 2016;387:537-544. https://doi.org/10.1016/S0140-6736(15)00979-4
  12. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 2014;35:765-776. https://doi.org/10.1093/eurheartj/eht542
  13. Moussa ID, Klein LW, Shah B, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol 2013;62:1563-1570. https://doi.org/10.1016/j.jacc.2013.08.720
  14. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  15. Kereiakes DJ, Ellis SG, Popma JJ, et al. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J 2015;170:641-651. https://doi.org/10.1016/j.ahj.2015.07.013
  16. Lane JP, Perkins LE, Sheehy AJ, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv 2014;7:688-695. https://doi.org/10.1016/j.jcin.2013.11.024
  17. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910. https://doi.org/10.1016/S0140-6736(09)60325-1
  18. Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention 2015;10:1160-1168. https://doi.org/10.4244/EIJY14M08_08
  19. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicenter GHOSTEU registry. EuroIntervention 2015;10:1144-1153. https://doi.org/10.4244/EIJY14M07_11
  20. Kawamoto H, Panoulas VF, Sato K, et al. Impact of strut width in periprocedural myocardial infarction: a propensity-matched comparison between bioresorbable scaffolds and the first-generation sirolimus-eluting stent. JACC Cardiovasc Interv 2015;8:900-909.
  21. Ishibashi Y, Muramatsu T, Nakatani S, et al. Incidence and potential mechanism(s) of post-procedural rise of cardiac biomarker in patients with coronary artery narrowing after implantation of an everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent. JACC Cardiovasc Interv 2015;8:1053-1063. https://doi.org/10.1016/j.jcin.2015.06.001
  22. Teeuwen K, Hubbers S, Tijssen JG, Van Der Heyden JA, Rensing BJ, Suttorp MJ. Experiences with the Absorb everolimus-eluting bioresorbable vascular scaffold in all comers: The St. Antonius Hospital single centre registry. Clin Trials Regul Sci Cardiol 2015;10:1-6. https://doi.org/10.1016/j.ctrsc.2015.09.004
  23. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010;56:1357-1365. https://doi.org/10.1016/j.jacc.2010.07.016
  24. Colombo A, Ruparelia N. Who is thrombogenic: the scaffold or the doctor? Back to the future! JACC Cardiovasc Interv 2016;9:25-27. https://doi.org/10.1016/j.jcin.2015.09.021
  25. Allahwala UK, Cockburn JA, Shaw E, Figtree GA, Hansen PS, Bhindi R. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. EuroIntervention 2015;10:1154-1159. https://doi.org/10.4244/EIJV10I10A190
  26. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-1837. https://doi.org/10.1016/j.jacc.2005.07.048

Cited by

  1. The euphoria, the warnings and the downfall of the current bioresorbale stents: could the journey be restarted? vol.33, pp.5, 2018, https://doi.org/10.3904/kjim.2018.060